[go: up one dir, main page]

SG10201600077RA - Combination - Google Patents

Combination

Info

Publication number
SG10201600077RA
SG10201600077RA SG10201600077RA SG10201600077RA SG10201600077RA SG 10201600077R A SG10201600077R A SG 10201600077RA SG 10201600077R A SG10201600077R A SG 10201600077RA SG 10201600077R A SG10201600077R A SG 10201600077RA SG 10201600077R A SG10201600077R A SG 10201600077RA
Authority
SG
Singapore
Prior art keywords
combination
Prior art date
Application number
SG10201600077RA
Inventor
Rakesh Kumar
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of SG10201600077RA publication Critical patent/SG10201600077RA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05Dipeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41551,2-Diazoles non condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/69Boron compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/005Enzyme inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG10201600077RA 2011-01-11 2012-01-11 Combination SG10201600077RA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161431508P 2011-01-11 2011-01-11

Publications (1)

Publication Number Publication Date
SG10201600077RA true SG10201600077RA (en) 2016-02-26

Family

ID=46507420

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201600077RA SG10201600077RA (en) 2011-01-11 2012-01-11 Combination
SG2013043856A SG191724A1 (en) 2011-01-11 2012-01-11 Combination

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG2013043856A SG191724A1 (en) 2011-01-11 2012-01-11 Combination

Country Status (15)

Country Link
US (6) US20130288984A1 (en)
EP (1) EP2663189B1 (en)
JP (1) JP6100700B2 (en)
KR (1) KR20140053836A (en)
CN (1) CN103298345B (en)
AU (1) AU2012205601B2 (en)
BR (1) BR112013017722A2 (en)
CA (1) CA2824201A1 (en)
EA (1) EA029000B1 (en)
ES (1) ES2689760T3 (en)
IL (1) IL227097B (en)
MX (1) MX356704B (en)
SG (2) SG10201600077RA (en)
WO (1) WO2012097021A1 (en)
ZA (1) ZA201304139B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4265300A3 (en) * 2013-10-01 2023-11-29 Novartis AG Combination
CA2929715A1 (en) * 2013-11-07 2015-05-14 Deciphera Pharmaceuticals, Llc Methods for inhibiting tie2 kinase useful in the treatment of cancer
CN118557737A (en) 2018-01-31 2024-08-30 德西费拉制药有限责任公司 Combination therapy for the treatment of gastrointestinal stromal tumors
CN111886006B (en) 2018-01-31 2024-07-09 德西费拉制药有限责任公司 Combination therapy for the treatment of mastocytosis
CN114615982A (en) 2019-08-12 2022-06-10 德西费拉制药有限责任公司 Ripoctinib for treating gastrointestinal stromal tumor
TWI878335B (en) 2019-08-12 2025-04-01 美商迪賽孚爾製藥有限公司 Methods of treating gastrointestinal stromal tumors
KR20250060322A (en) 2019-12-30 2025-05-07 데시페라 파마슈티칼스, 엘엘씨 Amorphous kinase inhibitor formulations and methods of use thereof
CN115243681B (en) 2019-12-30 2024-08-16 德西费拉制药有限责任公司 Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5604213A (en) 1992-03-31 1997-02-18 British Technology Group Limited 17-substituted steroids useful in cancer treatment
US5681835A (en) 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US6328590B1 (en) 2000-07-20 2001-12-11 Emc Corporation Methods and apparatus for controlling attachment of an electronic module with a circuit board connector
ES2551293T3 (en) * 2004-03-24 2015-11-17 Abbvie Inc. Tricyclic pyrazole kinase inhibitors
CN101039921A (en) 2004-10-13 2007-09-19 法玛西雅厄普约翰有限责任公司 Crystalline forms of 3-[5-chloro-4-[(2,4-difluorobenzyl)oxy]-6-oxopyrimidin-1(6h)-yl]-n-(2-hydroxyethyl)-4-methylbenzamide
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
AU2006282896A1 (en) * 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP1840114A1 (en) 2006-03-30 2007-10-03 LTB4 Sweden AB Crystalline Leukotriene B4
JP2009532497A (en) 2006-04-05 2009-09-10 ノバルティス アクチエンゲゼルシャフト Combination of therapeutic agents for treating cancer
WO2007122686A1 (en) 2006-04-14 2007-11-01 Eisai R & D Management Co., Ltd. Benzimidazole compounds
US20080051380A1 (en) 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
DK2061561T3 (en) 2006-08-25 2013-10-07 Janssen Oncology Inc CANCER TREATMENT COMPOSITIONS
JP4299327B2 (en) 2006-08-31 2009-07-22 トヨタ自動車株式会社 Variable valve timing device
US8828451B2 (en) * 2006-10-04 2014-09-09 University Of South Florida Akt sensitization of cancer cells
CL2007002948A1 (en) 2006-10-13 2008-05-30 Basf Ag 2-CHLORINE-5- (3,6-DIHYDRO-3-METHYL-2,6-DIOXO-4- (TRIFLUOROMETIL) -1- (2H)-PYRIMIDINYL) -4-FLUOR-N - ((METIL (1-METHYLETY) AMINO) SULFONILE] BENZAMIDE; PROCESS FOR THE PREPARATION OF SUCH HYDRATION; PHYTO-PROTECTION COMPOSITION; AND METHOD FOR CON
AR064010A1 (en) 2006-12-06 2009-03-04 Merck & Co Inc AKT ACTIVITY INHIBITORS
UY30892A1 (en) 2007-02-07 2008-09-02 Smithkline Beckman Corp AKT ACTIVITY INHIBITORS
RS53552B1 (en) 2007-10-11 2015-02-27 Astrazeneca Ab Pyrrolo[2,3-d]pyrimidin derivatives as protein kinase b inhibitors
WO2009067453A1 (en) * 2007-11-19 2009-05-28 Syndax Pharmaceuticals, Inc. Combinations of hdac inhibitors and proteasome inhibitors
DE102008044901A1 (en) 2008-08-29 2010-03-04 Siemens Aktiengesellschaft Method and device for selecting an irradiation plan and irradiation facility
CA2750565C (en) * 2009-01-30 2015-10-20 Glaxosmithkline Llc Crystalline n-{(1s)-2-amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1h-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride
AR078228A1 (en) 2009-06-26 2011-10-26 Novartis Ag CYP17 INHIBITORS
MX2012004140A (en) 2009-10-08 2012-09-07 Glaxosmithkline Llc Combination.
CN103857395A (en) 2011-04-01 2014-06-11 基因泰克公司 Combinations of AKT inhibitor compounds and abiraterone, and methods of use
AU2012250650A1 (en) 2011-05-03 2013-11-14 University Of Rochester Methods for treating prostate cancer
PH12014500122A1 (en) 2011-07-13 2014-03-24 Pharmacyclics Inc Inhibitors of bruton's tyrosine kinase
CA2851330C (en) 2011-10-10 2019-07-16 Zach System Process for preparing 17-substituted steroids
AU2013205648B2 (en) 2011-11-30 2015-02-05 Astrazeneca Ab Combination treatment
CA2875986C (en) 2012-06-04 2020-06-09 Pharmacyclics, Inc. Crystalline forms of a bruton's tyrosine kinase inhibitor
CA2923899A1 (en) 2013-10-01 2015-04-09 Novartis Ag Enzalutamide in combination with afuresertib for the treatment of cancer

Also Published As

Publication number Publication date
AU2012205601A1 (en) 2013-08-01
US20120258933A1 (en) 2012-10-11
US10449226B2 (en) 2019-10-22
EA029000B1 (en) 2018-01-31
US20160022641A1 (en) 2016-01-28
KR20140053836A (en) 2014-05-08
EP2663189B1 (en) 2018-07-04
EA201391027A1 (en) 2014-01-30
ES2689760T3 (en) 2018-11-15
US20160375086A1 (en) 2016-12-29
EP2663189A1 (en) 2013-11-20
JP2014507412A (en) 2014-03-27
EP2663189A4 (en) 2014-06-11
JP6100700B2 (en) 2017-03-22
SG191724A1 (en) 2013-08-30
WO2012097021A1 (en) 2012-07-19
ZA201304139B (en) 2014-02-26
AU2012205601B2 (en) 2016-03-24
CA2824201A1 (en) 2012-07-19
MX2013008074A (en) 2013-08-09
CN103298345B (en) 2016-12-14
CN103298345A (en) 2013-09-11
MX356704B (en) 2018-06-11
IL227097B (en) 2018-02-28
US20170100449A1 (en) 2017-04-13
US20130288984A1 (en) 2013-10-31
BR112013017722A2 (en) 2016-07-12
US20150119337A1 (en) 2015-04-30

Similar Documents

Publication Publication Date Title
GB201204966D0 (en) Djml
EP2754063A4 (en) Smb2 scaleout
ZA201304139B (en) Combination
HUE038998T2 (en) Hypoallergen
PL2606715T3 (en) Baler-wrapper combination
GB201216828D0 (en) Centraler
GB201103926D0 (en) Lock-alarm
GB201106465D0 (en) Cyclobuggy
GB201121105D0 (en) Combination
GB201117693D0 (en) Combination
GB201116007D0 (en) Combination
GB201106339D0 (en) Combination
GB201215297D0 (en) Psb-hinge-120828
GB201200646D0 (en) Nevadrop pickstrap
AU2011303V (en) Silverado Dianella tasmanica
GB201119965D0 (en) Tallymax
GB201117442D0 (en) Bedmate
GB201117393D0 (en) Swisaw
GB201116048D0 (en) Bumpa
GB201115563D0 (en) Goalstrike
GB201114306D0 (en) Pplicator
GB201113677D0 (en) eMeetMe
GB201113286D0 (en) Kh-1856hpp
GB201112164D0 (en) Kerb-vis
GB201112150D0 (en) Kerbeye